60940-34-3 Ebselen CAS NO.60940-34-3

ebselen usage and synthesis
description ebselen is one of the selenium-containing anti-inflammatory drugs.in 2003, rocha and co-workers identified diselenides as a new class of antiinflammatory agents.in 2014, nogueira and co-workers reported the synthesis and anti-inflammatory activity of salicyclic-based diselenides and selenocynates.recently, wilhelm and co-workers identified 4-phenylselenyl-7-chloroquinoline 270 as a potent antiinflammatory compound.
chemical properties yellow to beige crystalline powder
uses antioxidant, lipoxygenase inhibitor, inhibits oxidation of ldl
uses 2-phenyl-1,2-benzoselenazol-3-one acts as an antiinfammatory compounds,, in addition to that it acts as a modulator of kvβ subunits.
uses ebselen is a lipid-soluble organoselenium compound. numerous in vivo experiments have demonstrated that ebselen is able to inhibit both vasospasm and tissue damage in cerebral stroke/ischemia animal models (i.e. rat, mice, guinea pig and dog).for example, ebselen has been shown to provide significant protection against ischemic damage in both gray and white matter, and in the ventral posterior nucleus of rodent brains.additionally, administration of ebselen in gerbils significantly reduces neuronal death induced by ischemia and reperfusion in the hippocampal ca1 region.it has been reported that ebselen inhibits inositol monophosphatase and acts as a safe treatment for bipolar disorder.
the optimal gpx-like activity of ebselen was observed at neutral or nearphysiological ph (7.4), and the activity of ebselen was barely detected in acidic medium.during ischemia, brain ph falls rapidly within the first 5 min from 7.0 to 6.2, which is not optimal for ebselen's gpx-like activity.meanwhile, since ebselen has shown promising activity in the treatment of stroke, it seems that gpx-like activity of ebselen in the brain may not occur.thus, the enzymatic reduction of ebselen by trxr might be the main contribution to its antioxidant property during ischemia. unlike inorganic and aliphatic selenium compounds, ebselen does not liberate the selenium moiety, which remains within the ring structure. subsequent metabolism involves methylation, glucuronidation and hydroxylation. additionally, ebselen could also inhibit enzymes such as lipoxygenases, nitric oxide synthases, nitrogen oxides, protein kinase c and h1/k1-atpase.
besides the relationship with redox systems, another neuroprotective mechanism of ebselen is involved in controlling the expression of gaminobutyric acid shunt enzymes to supply the tricarboxylic acid cycle, and significantly inhibiting acetylcholinesterase activity,demonstrating its engagement in the metabolic system.